Evaluation of quality of life and emotional distress in endometrial cancer patients: A 2-year prospective, longitudinal study

Ferrandina, Gabriella; Petrillo, Marco; Mantegna, G.; Fuoco, Gilda; Terzano, Serena; Venditti, Laura; Marcellusi, Andrea; Vincenzo, Rosa De; Scambia, Giovanni

doi:10.1016/j.ygyno.2014.03.015

Cited by 56 publications

(60 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 The most frequent symptoms in our study on the other hand were lymphedema and menopausal symptoms. In a prospective longitudinal study by Ferrandina et al,11 in which EORTC QLQ-C30 and CX24 were used similar to ours, it was found that worse lymphedema scores were documented over time and menopausal symptoms dramatically worsened over time.…”

Section: Discussionsupporting

confidence: 72%

Assessing the Quality of Life in Patients With Endometrial Cancer Treated With Adjuvant Radiotherapy

Karabuga

Gültekin

Tulunay

et al. 2015

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 72%

Assessing the Quality of Life in Patients With Endometrial Cancer Treated With Adjuvant Radiotherapy

Karabuga

Gültekin

Tulunay

et al. 2015

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…Nout et al 156 demonstrated an equal or improved HRQoL as time progressed after diagnosis and initial treatment (TAH-BSO) compared with the general population. Although the PORTEC-2 RCT was based in the Netherlands, this finding was supported by the results of the other three studies, which were based in Italy, 159 Germany 157 and Turkey. 158 We therefore used the PORTEC-2 trial as our source of disutility for endometrial cancer compared with the general population.…”

Section: Endometrial Cancermentioning

confidence: 55%

“…Five studies [156][157][158][159][160] were identified that reported endometrial cancer quality-of-life estimates; two reported the PORTEC-2 (Postoperative Radiation Therapy for Endometrial Carcinoma) Phase III RCT at multiple time points, 156,160 which had the largest population (n = 427 at baseline, n = 80 at 10 years' follow-up) and longest follow-up (maximum 10 years) and compared the quality-of-life estimates for endometrial cancer with general population estimates. This trial included stage 1, high-risk endometrial cancer and reported HRQoL from the EORTC QLQ-C30.…”

Section: Endometrial Cancermentioning

confidence: 99%

Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation

Snowsill

Coelho

Huxley

et al. 2017

Health Technol Assess

112

View full text Add to dashboard Cite

BackgroundInherited mutations in deoxyribonucleic acid (DNA) mismatch repair (MMR) genes lead to an increased risk of colorectal cancer (CRC), gynaecological cancers and other cancers, known as Lynch syndrome (LS). Risk-reducing interventions can be offered to individuals with known LS-causing mutations. The mutations can be identified by comprehensive testing of the MMR genes, but this would be prohibitively expensive in the general population. Tumour-based tests – microsatellite instability (MSI) and MMR immunohistochemistry (IHC) – are used in CRC patients to identify individuals at high risk of LS for genetic testing.MLH1(MutL homologue 1) promoter methylation andBRAFV600E testing can be conducted on tumour material to rule out certain sporadic cancers.ObjectivesTo investigate whether testing for LS in CRC patients using MSI or IHC (with or withoutMLH1promoter methylation testing andBRAFV600E testing) is clinically effective (in terms of identifying Lynch syndrome and improving outcomes for patients) and represents a cost-effective use of NHS resources.Review methodsSystematic reviews were conducted of the published literature on diagnostic test accuracy studies of MSI and/or IHC testing for LS, end-to-end studies of screening for LS in CRC patients and economic evaluations of screening for LS in CRC patients. A model-based economic evaluation was conducted to extrapolate long-term outcomes from the results of the diagnostic test accuracy review. The model was extended from a model previously developed by the authors.ResultsTen studies were identified that evaluated the diagnostic test accuracy of MSI and/or IHC testing for identifying LS in CRC patients. For MSI testing, sensitivity ranged from 66.7% to 100.0% and specificity ranged from 61.1% to 92.5%. For IHC, sensitivity ranged from 80.8% to 100.0% and specificity ranged from 80.5% to 91.9%. When tumours showing low levels of MSI were treated as a positive result, the sensitivity of MSI testing increased but specificity fell. No end-to-end studies of screening for LS in CRC patients were identified. Nine economic evaluations of screening for LS in CRC were identified. None of the included studies fully matched the decision problem and hence a new economic evaluation was required. The base-case results in the economic evaluation suggest that screening for LS in CRC patients using IHC,BRAFV600E andMLH1promoter methylation testing would be cost-effective at a threshold of £20,000 per quality-adjusted life-year (QALY). The incremental cost-effectiveness ratio for this strategy was £11,008 per QALY compared with no screening. Screening without tumour tests is not predicted to be cost-effective.LimitationsMost of the diagnostic test accuracy studies identified were rated as having a risk of bias or were conducted in unrepresentative samples. There was no direct evidence that screening improves long-term outcomes. No probabilistic sensitivity analysis was conducted.ConclusionsSystematic review evidence suggests that MSI- and IHC-based testing can be used to identify LS in CRC patients, although there was heterogeneity in the methods used in the studies identified and the results of the studies. There was no high-quality empirical evidence that screening improves long-term outcomes and so an evidence linkage approach using modelling was necessary. Key determinants of whether or not screening is cost-effective are the accuracy of tumour-based tests, CRC risk without surveillance, the number of relatives identified for cascade testing, colonoscopic surveillance effectiveness and the acceptance of genetic testing. Future work should investigate screening for more causes of hereditary CRC and screening for LS in endometrial cancer patients.Study registrationThis study is registered as PROSPERO CRD42016033879.FundingThe National Institute for Health Research Health Technology Assessment programme.

show abstract

“…They concluded that menopausal and lymphedema symptoms heavily affect QOL in EC patients. Sexual Activity scores improved until the 12-month evaluation (p = .048), and showed a return to baseline levels at the last assessment (p = .025) (Ferrandina et al, 2014 (Carter et al, 2012).…”

Section: Ferrandina Et Al Assessed Qol and Emotional Distress In A Smentioning

confidence: 98%

Independent psychometric validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24)

et al. 2017

View full text Add to dashboard Cite

The endometrial cancer (EC)-specific Quality of Life module of the European Organization for Research and Treatment of Cancer (EORTC QLQ-EN24), was developed and validated in one study. We independently validated and assessed the psychometric properties of the instrument. Two hundred and eight women with EC before surgery, during adjuvant treatment and follow-up; in three different cancer centres completed the EORTC QLQ-C30 and the EN24. The questionnaire's completion rate was 100%, except sexuality items, that were answered by 35% of patients.All item-scale correlations for the multi-item scales exceeded the .4 criterion and correlated well with their own scale, while correlations with the other scales were low.The internal consistency of all multi-item scales were satisfactory (Cronbach's alpha coefficients ranging from .77 to .97). Discriminance for single-item scales was low. The QLQ-EN24 module discriminated well between clinically different patients, and there were no differences in quality of life questionnaire scales between patients with body mass index ≤30 when compared to those with >30. This validation study supports the reliability, as well as convergent and divergent validity of the EORTC QLQ-EN24. The module is a useful instrument for the assessment of QOL in patients with EC. However, data concerning sexuality should be interpreted with caution. K E Y W O R D Sendometrial cancer, quality of life, questionnaire, validation

show abstract

Evaluation of quality of life and emotional distress in endometrial cancer patients: A 2-year prospective, longitudinal study

Cited by 56 publications

References 28 publications

Assessing the Quality of Life in Patients With Endometrial Cancer Treated With Adjuvant Radiotherapy

Assessing the Quality of Life in Patients With Endometrial Cancer Treated With Adjuvant Radiotherapy

Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation

Independent psychometric validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24)

Contact Info

Product

Resources

About